NantHealth scores reimbursement for cancer testing service

NantHealth ($NH) got reimbursement to use its cancer test in clinical trials at some New Jersey-area health centers. The news is a feather in the cap of Dr. Patrick Soon-Shiong, who is priming his precision medicine venture for growth.

Horizon Blue Cross Blue Shield, New Jersey’s largest health insurance plan, will cover NantHealth’s GPS Cancer molecular test for investigational cancer studies for certain types of lung, breast and colon cancers. The hope is that the test could improve treatment while cutting costs.

Health systems ordering the company’s service include Cancer Institute of New Jersey, John Theurer Cancer Center and the University of Pennsylvania, NantHealth said in a statement.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The reimbursement marks a win for NantHealth, which is looking to expand its cancer profile analysis service. GPS Cancer uses whole-genome (DNA) sequencing, RNA sequencing and quantitative proteomics to give doctors a molecular profile of a patient’s cancer and potentially guide treatment.

NantHealth’s testing service already contributes to Cancer MoonShot 2020, a multipronged initiative from pharma, government and scientists to develop a cure-all cancer vaccine.

Reimbursement for GPS Cancer comes a few months after the company raised $91 million through an IPO. Existing investors including Soon-Shiong and Celgene ($CELG) bought $43 million of the stock, giving the company more fuel for the year ahead.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.